NAUT trades 9.6% below Wall Street's consensus target of $2.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NAUT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Nautilus Biotechnology, Inc. (NAUT) has a Wall Street consensus price target of $2.50, based on estimates from 5 covering analysts. With the stock currently trading at $2.28, this represents a potential upside of +9.6%. The company has a market capitalization of $290M.
Analyst price targets range from a low of $2.50 to a high of $2.50, representing a 0% spread in expectations. The median target of $2.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NAUT trades at a trailing P/E of -4.9x. Analysts expect EPS to grow -14.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
CDNACareDx, Inc | $1.4B | $26.18 | $27.00 | +3.1% | Buy | 28.0x | 13 |
SEERSeer, Inc. | $96M | $1.74 | $4.00 | +129.9% | Hold | — | 4 |
QBTSD-Wave Quantum Inc. | $9.1B | $24.69 | $33.25 | +34.7% | Buy | — | 13 |
ILMNIllumina, Inc. | $24.6B | $161.93 | $151.40 | -6.5% | Buy | 31.0x | 50 |
PACBPacific Biosciences of California, Inc. | $435M | $1.40 | $1.00 | -28.6% | Buy | — | 18 |
BFLYButterfly Network, Inc. | $2.3B | $8.90 | $5.42 | -39.1% | Buy | — | 7 |
TWSTTwist Bioscience Corporation | $5.5B | $87.56 | $75.00 | -14.3% | Buy | — | 13 |
BEAMBeam Therapeutics Inc. | $3.5B | $34.14 | $48.00 | +40.6% | Buy | — | 27 |
SRPTSarepta Therapeutics, Inc. | $1.9B | $17.53 | $25.14 | +43.4% | Buy | 5.0x | 54 |
TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
Quick answers to the most common questions about buying NAUT stock.
The consensus price target for NAUT is $2.5, close to the current price of $2.28 (9.6% implied move). Based on 5 analyst estimates, the stock appears fairly valued near current levels.
NAUT has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $2.5 implies 9.6% upside from current levels.
NAUT's current price is $2.28 with a consensus target of $2.5 (9.6% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $2.5 for NAUT, while the most conservative target is $2.5. The consensus of $2.5 represents the median expectation. These targets typically reflect 12-month expectations.
NAUT is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NAUT stock forecast based on 5 Wall Street analysts shows a consensus price target of $2.5, with estimates ranging from $2.5 (bear case) to $2.5 (bull case). The median consensus rating is "Buy".
NAUT appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $2.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NAUT analyst price targets range from $2.5 to $2.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $2.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.